Medical vs. surgical forms of endocrine therapy and risk for stroke, myocardial infarction

In recent years it has become increasingly evident that medical forms of endocrine therapy (i.e.,  androgen-deprivation therapy  or ADT) continue to be associated with a significant level of risk for cardiovascular diseases, including myocardial infarction (MI) and stroke. … READ MORE …

No PBRT center at OHSU after careful thought

According to a pre-Christmas report in The Oregonian, Oregon Health and Science University (OHSU) has decided not to go ahead with the development of a proton beam radiation therapy (PBRT) facility. The story is also covered on MedPage Today. … READ MORE …

Frequency of PSA testing and immediacy of prostate cancer treatment among men over 70

Two recent publications have offered evidence that, at 10 and 12 years of follow-up, the potential benefits of surgical treatment for low- and intermediate-risk prostate cancer did not include any impact on overall survival for men of 65 years of age or more at the time of surgery. … READ MORE …

Toxic side effects of adjuvant, salvage IMRT post-surgery

Prostate cancer patients are commonly concerned about the potential risks for side effects associated with adjuvant and salvage radiation therapy after a preceding, first-line, radical prostatectomy. … READ MORE …

FDA formalizes warning of cardiovascular risks for LHRH agonists

According to a media release from the U.S. Food and Drug Administration (FDA) yesterday, the agency has asked manufacturers of the class of drugs known as luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists to include warnings about risk for cardiovascular disease and diabetes in product labeling for these drugs. … READ MORE …

Intra-operative “fire” during RALP — a surgical complication to be avoided!

A recent paper in European Urology reports the first (known) case of an “intra-abdominal combustion” during a robot-assisted laparoscopic radical prostatectomy (RALP). … READ MORE …

US FDA reviewing the safety of LHRH agonists

For many years it has been understood by specialists that hormonal treatment of prostate cancer patients with luteinizing hormone releasing hormone (LHRH) agonists — also known as gonadatropin releasing hormone or GnRH agonists — is associated with metabolic side effects that include risks for cardiovascular disease and diabetes. … READ MORE …